Walmart Aktie WKN: 860853 / ISIN: US9311421039
Symbol: WMT

72,23EUR
+0,53EUR
+0,74%
22.06.2018
84,82USD
+0,61USD
+0,72%
22.06.2018
KAUFEN
VERKAUFEN

Analysen zu Walmart

13.06.18Walmart Equal-WeightMorgan Stanley
30.05.18Walmart NeutralCredit Suisse Group
18.05.18Walmart buyJefferies & Company Inc.
18.05.18Walmart HoldStifel, Nicolaus & Co., Inc.
18.05.18Walmart NeutralJP Morgan Chase & Co.
18.05.18Walmart Sector PerformRBC Capital Markets
17.05.18Walmart Sector PerformRBC Capital Markets
10.05.18Walmart Sector PerformRBC Capital Markets
10.05.18Walmart OutperformRBC Capital Markets
10.05.18Walmart neutralWells Fargo & Co
10.05.18Walmart buyMorningstar
10.05.18Walmart NeutralCredit Suisse Group
10.05.18Walmart OutperformTelsey Advisory Group
02.05.18Walmart HoldStifel, Nicolaus & Co., Inc.
02.05.18Walmart HoldMorningstar
30.04.18Walmart Sector PerformRBC Capital Markets
30.04.18Walmart NeutralJP Morgan Chase & Co.
16.04.18Walmart Conviction BuyGoldman Sachs Group Inc.
08.03.18Walmart NeutralCredit Suisse Group
02.03.18Walmart neutralOppenheimer & Co. Inc.
21.02.18Walmart NeutralUBS AG
21.02.18Walmart Conviction BuyGoldman Sachs Group Inc.
21.02.18Walmart NeutralJP Morgan Chase & Co.
21.02.18Walmart HoldStifel, Nicolaus & Co., Inc.
21.02.18Walmart OutperformTelsey Advisory Group
16.02.18Walmart buyJefferies & Company Inc.
16.02.18Walmart Conviction BuyGoldman Sachs Group Inc.
16.02.18Walmart NeutralUBS AG
26.01.18Walmart overweightBarclays Capital
23.01.18Walmart NeutralJP Morgan Chase & Co.
18.01.18Walmart Conviction Buy ListGoldman Sachs Group Inc.
18.01.18Walmart NeutralMacquarie Research
16.01.18Walmart NeutralGoldman Sachs Group Inc.
05.01.18Walmart Sector PerformRBC Capital Markets
04.01.18Walmart NeutralUBS AG
02.01.18Walmart OutperformRBC Capital Markets
21.12.17Walmart neutralWells Fargo & Co
19.12.17Walmart buyCitigroup Corp.
29.11.17Walmart Sector PerformRBC Capital Markets
20.11.17Walmart NeutralGoldman Sachs Group Inc.
Seite: 123456789...15

Kursziele Walmart Aktie

+14,65%Abstand aktueller Kurs zum Ø Kursziel: +14,65%
Ø Kursziel: 97,25
Anzahl:
Buy: 6
Hold: 9
Sell: 0
80
90
100
110
120
130
Citigroup Corp.
117 $
Macquarie Research
85 $
Barclays Capital
120 $
Telsey Advisory Group
110 $
UBS AG
103 $
Oppenheimer & Co. Inc.
93 $
Goldman Sachs Group Inc.
99 $
Telsey Advisory Group
105 $
Morningstar
91 $
Wells Fargo & Co
85 $
RBC Capital Markets
90 $
JP Morgan Chase & Co.
87 $
Stifel, Nicolaus & Co., Inc.
87 $
Jefferies & Company Inc.
106 $
Credit Suisse Group
85 $
Morgan Stanley
93 $
Abstand aktueller Kurs zum Ø Kursziel: +14,65%
Ø Kursziel: 97,25
alle Walmart Kursziele

Aktuelle News zu

23:03 UhrGCL System Integration stellt hocheffiziente Module auf Intersolar aus
22:23 UhrBERLINER MORGENPOST: Erdogans hohes Risiko / Leitartikel von Gudrun Büscher
21:33 UhrBERLINER MORGENPOST: Berlin braucht "Große Gelbe" / Kommentar von Andreas Abel
20:59 UhrGCL System Integration stellt hocheffiziente Module auf Intersolar aus
20:23 UhrHanergy stellt seine jüngsten Innovationen auf der Intersolar Europe aus
19:47 UhrPositionen der deutschen und europäischen Verlegerverbände zum EU-Leistungsschutzrecht
19:45 UhrAthletic Brewing Company Launches State-Wide in Connecticut
19:30 UhrOne Drop Announces Blood Glucose Prediction and Automated Decision Support
19:01 UhrDiabeloop Insulin Delivery System May Significantly Improve Glycemic Control for People with Type 1 Diabetes
18:43 UhrThe Stars Group gibt Start des privaten Angebots von unbesicherten Schuldscheinen in Höhe von 750 Millionen USD bekannt
18:43 UhrFully Implantable, Continuous Glucose Monitoring Sensor Provided Accuracy for Six Months in Adolescents and Adults with Type 1 Diabetes
18:43 UhrDual-Hormone, Artificial Pancreas with Insulin and Pramlintide Significantly Improves Glucose Levels, Compared to Insulin-Only Artificial Pancreas
18:40 UhrOmnipod® Hybrid Closed-Loop Insulin Delivery System Significantly Improves Glycemic Control in Adults with Type 1 Diabetes
18:30 UhrVIA Opens Newest Park & Ride Facility in Stone Oak
18:30 UhrVieles spricht für Emerging Markets
18:27 UhrSpotify räumt beim Cannes Lions Festival of International Creativity ab
18:19 UhrHanergy stellt seine jüngsten Innovationen auf der Intersolar Europe aus
17:00 UhrImportant Questions To Ask Car Insurance Agents
16:57 UhrDer Tagesspiegel: Schäuble: Merkel bleibt bei einer Richtlinienentscheidung keine Wahl
16:30 UhrUnifor locals reach tentative agreements with Bombardier
16:30 UhrUnifor locals reach tentative agreements with Bombardier
16:23 UhrSpotify räumt beim Cannes Lions Festival of International Creativity ab
16:12 UhrTresiba® demonstrated significantly lower A1C and rates of hypoglycaemia versus insulin glargine U-300 in real-world evidence study
16:12 UhrTresiba® Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Versus Insulin Glargine U300 in Real-World Evidence Study
16:12 UhrTresiba® Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Versus Insulin Glargine U300 in Real-World Evidence Study
16:09 UhrOzempic® provided greater weight reductions for adults with a baseline BMI =25kg/m2 than those with lower baseline BMI <25kg/m2, in a SUSTAIN 7 post-hoc analysis
16:09 UhrOzempic® Provided Greater Weight Reductions for Adults With a Baseline BMI =25kg/m2 Than Those With Lower Baseline BMI <25kg/m2, in a SUSTAIN 7 Post-hoc Analysis
16:09 UhrOzempic® Provided Greater Weight Reductions for Adults With a Baseline BMI =25kg/m2 Than Those With Lower Baseline BMI <25kg/m2, in a SUSTAIN 7 Post-hoc Analysis
16:06 UhrOral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial
16:06 UhrOral Semaglutide Demonstrated Significant Reduction in Blood Sugar vs Placebo in PIONEER 1 Trial
16:06 UhrOral Semaglutide Demonstrated Significant Reduction in Blood Sugar vs Placebo in PIONEER 1 Trial
16:03 UhrOne Third of Participants in a Workforce Study Reduce Risk for Diabetes after Employer Wellness Screening and Behavioral Counseling, Finds Quest Diagnostics Study
16:00 UhrGNation Shows That Gamers Care About Charity at E3 2018
16:00 UhrDr. John R. Burroughs of Springs Aesthetics Now Offering vFit PLUS Feminine Wellness Treatment Device
16:00 UhrReal-World Evidence Shows Oral INVOKANA® (canagliflozin) Results in Greater Weight Loss and Treatment Adherence Than Injectable GLP-1 Receptor Agonists in Type 2 Diabetes Patients
16:00 UhrFractyl Announces Presentation of Key Scientific Research at ADA 2018 Indicating That Modern Diets Durably Alter Duodenal Lining, Highlighting the Intestine's Role in Type 2 Diabetes and NASH
16:00 UhrNew Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce Potential of Lilly's Ultra Rapid Lispro in People with Type 1 and Type 2 Diabetes
16:00 UhrJardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors
16:00 UhrADT NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against ADT Inc. - ADT
16:00 UhrTresiba® demonstrated significantly improved blood sugar control and lower rates of hypoglycemia versus insulin Toujeo® in real-world evidence study
16:00 UhrTresiba® demonstrated significantly improved blood sugar control and lower rates of hypoglycemia versus insulin Toujeo® in real-world evidence study
15:47 UhrGaumard's Growing Family Takes Center Stage at AWHONN '18
15:30 UhrPflichtblatt für Ihr Geld: Neue €uro am Sonntag
15:00 UhrBay Shore Area Dealership Partners with Animal Rescue for Adoption Event
15:00 UhrStatement by the Prime Minister on the National Day of Remembrance for Victims of Terrorism
15:00 UhrStatement by the Prime Minister on the National Day of Remembrance for Victims of Terrorism
14:53 UhrEin Prosit auf die Bierbranche: Das sind die wahren WM-Sieger
14:05 UhrSignificant blood sugar improvement with Xultophy® 100/3.6 compared to insulin glargine U-100 when used as add-on to oral diabetes medications
14:05 UhrSignificant Blood Sugar Improvement With Xultophy® Compared to Insulin Glargine U-100 When Used as Add-On to Oral Diabetes Medications
14:00 UhrNew Data Show Amgen's Repatha® (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes

Online Brokerage über finanzen.net

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
Zur klassischen Ansicht wechseln
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Daimler AG710000
Apple Inc.865985
Scout24 AGA12DM8
Amazon906866
TeslaA1CX3T
Volkswagen (VW) AG Vz.766403
Allianz840400
Alphabet C (ex Google)A14Y6H
MasterCard Inc.A0F602
Netflix Inc.552484
Facebook Inc.A1JWVX
E.ON SEENAG99
BMW AG519000
Deutsche Telekom AG555750